Natera (NTRA) said Monday the data from a study showed its Signatera molecular residual disease test identified patients with resected colorectal liver metastases who benefited from adjuvant chemotherapy.
The company said the analysis included 298 patients from the trial with a median follow-up of 43 months.
Among certain patients who had surgery without prior chemotherapy, adjuvant chemotherapy significantly improved overall survival and disease-free survival versus observation, the company said.
Four-year overall survival was 65.3% with chemotherapy versus 32.9% without, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments